Attached files

file filename
EX-99.1 - WOUND MANAGEMENT TECHNOLOGIES, INC.wmti8kex991032210.htm



Washington, D.C. 20549



Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported):    March 22, 2010

Wound Management Technologies, Inc.

(Exact name of Company as specified in its charter)





(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)


777 Main Street, Suite 3100, Fort Worth, Texas 


(Address of principal executive offices)

(Zip Code)


Registrant’s telephone number, including area code:   817-820-7080 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 7.01. Regulation FD Disclosure.

Ms. Deborah Jenkins Hutchinson, President Wound Management Technologies, Inc., released a letter to the shareholders pertaining to the direction of the company and a copy of the letter is furnished as Exhibit 99.1 hereto and are incorporated herein by reference.

The information in this report is being furnished pursuant to Regulation FD.  In accordance with General Instructions B.2 and B.6 of Form 8-K, the information in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1934, as amended.  The furnishing of the information set forth in this report is not intended to, and does not, constitute a determination or admission as to the materiality or completeness of such information.

Item 9.01 Exhibits

(d)     Exhibits.

99.1     Letter from the President.


     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Wound Management Technologies, Inc.  
Date: March 22, 2010    
    /s/Scott A. Haire    
    Scott A. Haire, Chairman of the Board,  
    Chief Executive Officer  
    And (Principal Financial Officer)